Comments on: Midatech Pharma MTX110 could double rare brain tumour survival beyond a year https://ukinvestor.foxrobinson.com/midatech-pharma-mtx110-could-double-rare-brain-tumour-survival-beyond-a-year/ Tue, 03 Nov 2020 17:42:32 +0000 hourly 1 https://wordpress.org/?v=6.6.2 By: Sky Medical launches Geko to tackle blood clots in UK's ageing population - The Investment Observer https://ukinvestor.foxrobinson.com/midatech-pharma-mtx110-could-double-rare-brain-tumour-survival-beyond-a-year/#comment-16225 Tue, 03 Nov 2020 17:42:32 +0000 https://ukinvestor.foxrobinson.com/?p=31861#comment-16225 […] the condition being more common in elderly groups, Sky Medical Technology launched a bioelectronic medicine therapy, OnPulse, to reduce the prevalence of blood clots in the UK’s growing, ageing […]

]]> By: GSK and Sanofi sign Statement of Intent to provide 200m COVID vaccines - UK Investor Magazine https://ukinvestor.foxrobinson.com/midatech-pharma-mtx110-could-double-rare-brain-tumour-survival-beyond-a-year/#comment-16181 Wed, 28 Oct 2020 13:10:34 +0000 https://ukinvestor.foxrobinson.com/?p=31861#comment-16181 […] Sanofi (EPA:SAN) have signed a Statement of Intent with Gavi, for the supply of 200 million COVID vaccine […]

]]> By: Pharma M&A deal value fell by more than 92% year-on-year - UK Investor Magazine https://ukinvestor.foxrobinson.com/midatech-pharma-mtx110-could-double-rare-brain-tumour-survival-beyond-a-year/#comment-16165 Mon, 26 Oct 2020 14:16:29 +0000 https://ukinvestor.foxrobinson.com/?p=31861#comment-16165 […] appear to be a positive shift, given the economic impacts of the pandemic. However, the rise in pharma industry deals might not come as a surprise to some, and it is worth noting that the deals being […]

]]>